SCHEMBL30786149

SCHEMBL30786149

C=Cc1ccc(CN(C)C)cn1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.44
CHRNA4 P43681 1/20 0.44
HRH3 Q9Y5N1 2/20 0.43
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
PYCR1 P32322 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
SMO Q99835 1/20 0.33
BTK Q06187 1/20 0.33
SRC P12931 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30786141 0.81 HRH3 (0.47) HRH3KDM4EL3MBTL1HDAC6
SCHEMBL30786186 0.81 HRH3 (0.47) HRH3KDM4EL3MBTL1HDAC6
SCHEMBL15007 0.78 KDM4E (0.61) HRH3KDM4EL3MBTL1NOS3NOS1
SCHEMBL7845108 0.75 HRH3 (0.50) CHRNB2CHRNA4HRH3L3MBTL1ALDH1A1
SCHEMBL19735731 0.74 KDM4E (0.45) KDM4EL3MBTL1ALDH1A1TSHR
SCHEMBL14878746 0.74 KDM4E (0.39) KDM4EL3MBTL1BTK
SCHEMBL2622782 0.74 RRM2 (0.50) HRH3KDM4EL3MBTL1BTK
SCHEMBL11124858 0.74 ALDH1A1 (0.41) KDM4EL3MBTL1ALDH1A1TSHRBTK
SCHEMBL2133032 0.74 KDM4E (0.43) KDM4EL3MBTL1TSHRBTKPOLB
SCHEMBL11010879 0.74 KDM4E (0.39) KDM4EL3MBTL1BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 CHRNB2 3285/4885CHRNA4 4788/4885HRH3 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.